Innohep (Tinzaparin Sodium)

Innohep (tinzaparin sodium) is used in the venous thromboembolism pathway to prevent and manage clot formation.

• Deep vein thrombosis (prevention): reduces incidence of clot formation in at‑risk patients.
• Deep vein thrombosis (treatment): facilitates resolution of existing thrombi and prevents extension.
• Pulmonary embolism (prevention): lowers risk of embolic events in patients with DVT or other risk factors.
• Haemodialysis (anticoagulation): provides anticoagulant support during extracorporeal dialysis circuits.

• Tinzaparin sodium binds to antithrombin III, markedly enhancing its inhibition of activated factor Xa and, to a lesser extent, thrombin (factor IIa). This accelerates the inactivation of clotting factors within the coagulation cascade, thereby reducing thrombin generation and preventing the formation and propagation of fibrin clots.

Tinzaparin sodium may be associated with bleeding‑related and immune‑mediated reactions.

Common Side Effects

• Injection site pain or erythema.
• Minor bruising or hematoma at the injection site.
• Mild gastrointestinal bleeding.
• Transient thrombocytopenia.
• Elevated liver enzymes.

Serious or Rare Side Effects

• Major hemorrhage (intracranial, gastrointestinal).
• Heparin‑induced thrombocytopenia (HIT) with paradoxical thrombosis.
• Spinal or epidural hematoma.
• Severe allergic reaction (anaphylaxis).
• Disseminated intravascular coagulation (rare).

When prescribing Innohep, clinicians should evaluate patient‑specific risk factors and monitor therapy closely.

• Renal impairment: assess dosing and monitor anti‑Xa levels.
• History of bleeding: weigh benefits against increased bleeding risk.
• Concurrent anticoagulants or antiplatelet agents: avoid or adjust therapy to limit bleeding.
• Pregnancy: use only if potential benefit justifies potential risk to fetus.
• Upcoming surgery or invasive procedures: discontinue according to clinical guidelines.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Tinzaparin sodium can interact with several agents that affect hemostasis or drug metabolism.

Major Interactions (Avoid)

• Other parenteral anticoagulants (e.g., unfractionated heparin, fondaparinux): additive anticoagulant effect.
• Direct thrombin inhibitors (e.g., dabigatran): increased bleeding risk.
• Thrombolytic agents (e.g., alteplase): synergistic hemorrhagic potential.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding.
• Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: heightened bleeding tendency.
• Corticosteroids: potential for mucosal bleeding.
• ACE inhibitors: rare reports of enhanced anticoagulant effect.